<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005600</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067713</org_study_id>
    <secondary_id>RMNHS-1489</secondary_id>
    <secondary_id>EU-20004</secondary_id>
    <nct_id>NCT00005600</nct_id>
  </id_info>
  <brief_title>Axillary Drainage Following Lymph Node Dissection in Women With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>Optimum Drainage of the Axilla After Lymph Node Dissection: A Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: The use of axillary drains may help to prevent complications following axillary&#xD;
      lymph node dissection.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is comparing three methods of axillary drainage to&#xD;
      see how well they work following lymph node dissection in women with stage I or stage II&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare high vacuum drainage vs low vacuum drainage vs simple tube drainage in patients&#xD;
           undergoing axillary surgery for stage I or II breast cancer.&#xD;
&#xD;
      OUTLINE: This is a randomized study.&#xD;
&#xD;
      Patients undergo axillary dissection, then are randomized to one of three axillary drainage&#xD;
      systems.&#xD;
&#xD;
        -  Arm I: Patients receive high vacuum drainage.&#xD;
&#xD;
        -  Arm II: Patients receive low vacuum drainage.&#xD;
&#xD;
        -  Arm III: Patients receive simple tube drainage (no vacuum). All drains are removed when&#xD;
           daily volumes are below 30 mL or at 5 days after surgery, regardless of drain volume.&#xD;
&#xD;
      Patients are followed at day 10 and at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 1997</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Lymphedema</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of resectable stage I or II breast cancer&#xD;
&#xD;
          -  Planned primary surgery of level II or III axillary dissection in association with one&#xD;
             of the following:&#xD;
&#xD;
               -  Wide local excision (may be done through separate incision)&#xD;
&#xD;
               -  No breast surgery&#xD;
&#xD;
               -  Bilateral surgery allowed&#xD;
&#xD;
          -  No prior mastectomy&#xD;
&#xD;
          -  No immediate breast reconstruction using implants, latissimus dorsi, or rectus&#xD;
             abdominus myocutaneous flaps at primary operation&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior axillary surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>lymphedema</keyword>
  <keyword>perioperative/postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

